
- Pharmaceutical Technology\'s In the Lab eNewsletter-06-05-2019
- Volume 14
- Issue 6
Portfolio of Tools to Advance Immunotherapy
Agilent’s updated portfolio of products for immunotherapy researchers provides cell-based tools for translational research and development.
Agilent Technologies has updated its portfolio of products for immunotherapy researchers. The company’s new offering includes four purpose-built components that complement the following:
- SureGuide Chemically Synthesized sgRNAs: to deliver guides to enable the full potential of CRISPR for cellular engineering and immunotherapy
- NovoCyte Quanteon Flow Cytometer: to immunophenotype with up to 25 channels of fluorescence using sensitive silicon photomultiplier detector technology
- xCELLigence RTCA eSight: to capture dynamic cell behavior and follow the biology that can be missed by labor-intensive endpoint assays to quantify critical events, such as cancer-cell elimination, in real time.
- Seahorse XF Analyzers: to discover and tune immune-cell metabolism to mount a sustained and robust anti-tumor response.
“Immunotherapy is changing the landscape of cancer treatment, but most of the available tools are adapted and not purpose-built for this cell-centric workflow,” said David Ferrick, PhD, senior director of the cell analysis division at Agilent Technologies, in a company press release. “This is why we have placed so much emphasis on assembling and harmonizing innovative cell-based solutions. We want to enable researchers and developers to overcome the challenges and capture the opportunities of this rapidly growing field.”
“To find the answers, flow cytometry approaches, kinetic measures of live-cell metabolism, and quantifying the ability of T cells to kill targets over time, are all aspects that can be investigated now with the tools that Agilent provides,” said Carl June, MD, professor in immunotherapy at the Perelman School of Medicine at the University of Pennsylvania and Abramson Cancer Center, in the release. “Any cell-based assay that improves the probability that you’re going to have an effective cell product will be something that everyone wants.”
The solution was showcased at Immunology 2019, the 103rd annual meeting of the American Association of Immunologists, which took place in San Diego, CA, on May 9–13, 2019.
Source:
Articles in this issue
over 6 years ago
Cleaning Validation for Biologic Equipmentover 6 years ago
Automatic Pretreatment System for Cell Culture Media Analysisover 6 years ago
Metrohm’s Acquisition of B&W Tek Boosts Spectroscopy Portfolioover 6 years ago
Knauer Offers New Separation Columns and Screening Servicesover 6 years ago
New Compound Discovered that Kills Antibiotic-Resistant Microbesover 6 years ago
FDA Publishes Guidance on Therapeutic Protein Biosimilarsover 6 years ago
NIH Awards Grants to Advance STI Vaccine Developmentover 6 years ago
Advancing Cell Therapy for Diabetesover 6 years ago
AstraZeneca, BenevolentAI Partner on AI for Drug DiscoveryNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





